Cardioprotection in AML (NCT04977180) | Clinical Trial Compass
RecruitingPhase 2
Cardioprotection in AML
United States70 participantsStarted 2022-03-04
Plain-language summary
Patients with acute myeloid leukemia (AML) often receive a drug called daunorubicin. Daunorubicin is a type of drug called an anthracycline, which increases the risk of some damage to the heart. Beta blockers and angiotensin-converting enzyme inhibitors (ACEi) are two types of drugs that are often used (and are FDA approved) to treat the type of damage to the heart caused by anthracyclines. They have also been used in some populations to prevent this type of heart damage. In this study, participants will be randomly assigned to either preventively take a beta blocker and ACEi or not to receive these. The primary purpose of the study is to look at how often people in each group develop this type of heart damage. The study investigators will also collect data about your quality of life and other changes in your heart function.
Frequency and severity of anthracycline-induced cardiotoxicity among patients receiving acute myeloid leukemia (AML) chemotherapy is unknown. We hypothesize that up-titrating study agents to maximum tolerated dosage at the time of induction (starting treatment for AML) will prevent the development of systolic dysfunction as determined on serial echocardiography.
Who can participate
Age range18 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Signed informed consent obtained prior to conducting any study-specific screening procedures.
✓. Willing and able to understand the nature of this study and to comply with both the study as well as follow-up procedures for the duration of the study.
✓. Age ≥ 18 years old with newly-diagnosed Acute Myeloid Leukemia (AML)
✓. ECOG performance status must be ≤ 2
✓. Planning to receive initial induction therapy containing an anthracycline for AML. Participants may have started initial induction therapy if anthracycline has not yet been administered.
✓. Adequate organ function as evidenced by the following laboratory findings:
✓. Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or \< 3 x ULN for patients with Gilbert's Syndrome
✓. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN
Exclusion criteria
✕
What they're measuring
1
Left ventricular ejection fraction (LVEF)
Timeframe: Baseline through 90 days after first day of last cycle of anthracycline (usually up to 6 months later)
. Ongoing use of any beta blocker, ACEi, or angiotensin II receptor agonist (ARB) at the time of pre-enrollment screening.
✕. Uncontrolled, intercurrent illnesses including but not limited to symptomatic unstable angina pectoris, cardiac arrhythmias not well controlled with medications, myocardial infarction in the 6 months preceding registration or psychiatric illness/social situations that would limit compliance with study requirements as determined by the study personnel, all at the discretion of the treating oncologist.
✕. Patient receiving concurrent investigational agents, or those who have received an investigational agent within one week of registration.